Literature DB >> 10586387

The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment.

P B Dews1, G L Curtis, K J Hanford, C P O'Brien.   

Abstract

Reports of symptoms when regular caffeine consumption is stopped have appeared in the medical literature, but the frequency and significance of this phenomenon have remained controversial. The objective of this study was to collect information on the prevalence and severity of caffeine withdrawal in the general population and determine the incidence and type of symptoms reported on blind abrupt and gradual caffeine cessation among coffee drinkers reporting past episodes of caffeine-withdrawal symptoms. A community-based telephone survey was followed by a stratified, randomized, double-blind controlled study. Participants included 11,112 persons spontaneously calling to inquire about studies not related to caffeine and 57 regular caffeine users selected from among the callers because of self-reported caffeine-withdrawal symptoms. Gradual or abrupt withdrawal from caffeine was compared to continuation of the same caffeine level. In a survey of 11,112 persons, 61% reported daily caffeine consumption, and 11% of the caffeine consumers reported symptoms upon stopping caffeine. Among the regular caffeine users, only 0.9% of males and 5.5% of females reported symptoms significant enough to interfere with normal activities when they abruptly stopped caffeine. A group of those reporting withdrawal symptoms were randomly assigned to three subsamples. In the group subjected to abrupt withdrawal (N = 18), 6 (33.3%) reported symptoms (e.g., headaches and tiredness). Including decreases in functional ratings, a total of 7 of the 18 (38.8%) could be considered to have experienced caffeine withdrawal. The gradual withdrawal group (N = 20) reported minimal if any caffeine withdrawal symptoms. A third group (N = 18) was kept on a level dose of caffeine for comparison. When participants are unaware of the caffeine-withdrawal focus of the study, these results suggest that both the frequency and severity of caffeine-withdrawal symptoms are much lower than found in some previous reports and that clinically significant symptoms may be uncommon events among the general population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586387     DOI: 10.1177/00912709922012024

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features.

Authors:  Laura M Juliano; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-21       Impact factor: 4.530

Review 2.  Caffeine use in children: what we know, what we have left to learn, and why we should worry.

Authors:  Jennifer L Temple
Journal:  Neurosci Biobehav Rev       Date:  2009-01-20       Impact factor: 8.989

Review 3.  A benefit-risk assessment of caffeine as an analgesic adjuvant.

Authors:  W Y Zhang
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Fourteen well-described caffeine withdrawal symptoms factor into three clusters.

Authors:  Stephen Ozsungur; Darren Brenner; Ahmed El-Sohemy
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

5.  Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.

Authors:  Emma Childs; Christa Hohoff; Jürgen Deckert; Ke Xu; Judith Badner; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

6.  High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study.

Authors:  Knut Hagen; Kari Thoresen; Lars Jacob Stovner; John-Anker Zwart
Journal:  J Headache Pain       Date:  2009-03-24       Impact factor: 7.277

7.  Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users.

Authors:  Emma Childs; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.